Clinical Trial Update: Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating albiglutide added to basal-bolus insulin therapy in Type 2 diabetes mellitus was withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Albiglutide (albiglutide)
• Insulin, basal-bolus regimen (insulin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: WITHDRAWN